PortView
La Jolla Pharmaceutical (LJPC) Stock Analysis
NASDAQHealthcareBiotechnology
What La Jolla Pharmaceutical does
La Jolla Pharmaceutical Company is dedicated to the creation and marketing of therapeutic solutions, with the ultimate goal of enhancing patient outcomes in the face of life-threatening illnesses. The company's commercialized offerings include GIAPREZA, a potent vasoconstrictor designed to raise blood pressure in adult patients afflicted by septic or other forms of distributive shock. Additionally, it provides XERAVA, a tetracycline-class antibacterial effective in treating complex intra-abdominal infections in individuals aged 18 and above. These vital medications are supplied to hospitals and other healthcare institutions exclusively within the United States. Looking ahead, La Jolla is actively advancing several investigational drug candidates through early-stage clinical or preclinical development. These encompass TP-6076, an intravenous fluorocycline derivative targeting specific multidrug-resistant gram-negative bacteria; TP-271, a fluorocycline available for both intravenous and oral administration, intended to address respiratory conditions stemming from bacterial biothreats, antibiotic-resistant public health pathogens, and community-acquired bacterial pneumonia; and TP-2846, an intravenous tetracycline being explored for its potential in treating acute myeloid leukemia. The company has forged key strategic partnerships, including a licensing agreement with Everest Medicines Limited for the development and commercialization of XERAVA. Furthermore, it holds a similar agreement with PAION AG for the commercialization of both GIAPREZA and XERAVA. Founded in 1989 and headquartered in Waltham, Massachusetts, La Jolla Pharmaceutical Company has operated as a subsidiary of Innoviva, Inc. since August 22, 2022.
Key metrics
ETFs linked to LJPC
Broad-market and Healthcare sector ETFs an investor holding La Jolla Pharmaceutical is often also exposed to. Open an ETF page to see its actual top holdings.
PortView Portfolio Insights
PortView analyzes how LJPC fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.
Analyze LJPC in PortView →Similar companies
Frequently asked questions
- What is the ticker symbol for La Jolla Pharmaceutical?
- La Jolla Pharmaceutical trades under the ticker LJPC on NASDAQ.
- Which exchange is LJPC listed on?
- LJPC is listed on NASDAQ.
- What sector does La Jolla Pharmaceutical operate in?
- La Jolla Pharmaceutical is classified in the Healthcare sector (Biotechnology industry).
- How can PortView help analyze LJPC in a portfolio?
- PortView shows LJPC's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.
The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.